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  GENERAL ORTHOPAEDICS
Systematic review assessing the 
evidence for the use of stem cells in 
fracture healing
Aims
Bone demonstrates good healing capacity, with a variety of strategies being utilized to en-
hance this healing. One potential strategy that has been suggested is the use of stem cells to 
accelerate healing.
Methods
The following databases were searched: MEDLINE, CENTRAL, EMBASE, Cochrane Database 
of Systematic Reviews, WHO- ICTRP,  ClinicalTrials. gov, as well as reference checking of in-
cluded studies. The inclusion criteria for the study were: population (any adults who have 
sustained a fracture, not including those with pre- existing bone defects); intervention (use 
of stem cells from any source in the fracture site by any mechanism); and control (fracture 
healing without the use of stem cells). Studies without a comparator were also included. The 
outcome was any reported outcomes. The study design was randomized controlled trials, 
non- randomized or observational studies, and case series.
Results
In all, 94 eligible studies were identified. The clinical and methodological aspects of the 
studies were too heterogeneous for a meta- analysis to be undertaken. A narrative synthesis 
examined study characteristics, stem cell methods (source, aspiration, concentration, and 
application) and outcomes.
Conclusion
Insufficient high- quality evidence is available to determine the efficacy of stem cells for frac-
ture healing. The studies were heterogeneous in population, methods, and outcomes. Work 
to address these issues and establish standards for future research should be undertaken.
Cite this article: Bone Joint Open 2020;1-10:622–632.
Keywords: systematic review, stem cells, Fracture
Introduction
Bone demonstrates excellent healing 
capacity, although the process by which this 
occurs is not well understood. The healing 
process is broadly split into three overlap-
ping phases, inflammation, bone production 
and bone remodelling. A number of growth 
factors and various signalling molecules 
are responsible for bone healing. In all, 20 
million people worldwide suffer from bone 
loss either from trauma or disease, leading to 
five million interventions.1
Overall, 10%of fractures may not heal and 
require further intervention.2 Delayed union 
and nonunion are expensive and burden-
some to both patients and the healthcare 
system, with patients experiencing psycho-
logical distress and physical dysfunction, 
leading to a loss of working days. The esti-
mated cost of treating nonunion is substan-
tial across many healthcare settings.3-5
Multiple strategies can be employed to 
enhance bone healing; stability of bony 
construct, good bony contact and adequate 
vascularity to deliver cells, and growth 
factors. Alternate systemic and local thera-
pies are developed to further augment the 
bone healing.6
The option of stem cells to enhance the 
rate of bone healing in acute fractures and 
improve bone healing in delayed/nonunion 
or in bone defects is of great interest to 
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clinicians but not well understood. The osteogenic 
potential of mesenchymal stem cells has been proven 
repeatedly in a number of human and animal studies,7 
it has been shown that these cells are found in not only 
bone marrow but also adipose, periosteum, synovium 
and muscle tissue. One strategy that has been developed 
is the diamond concept which couples the current strat-
egies of bone healing with the use stem cells in to a four 
part method.6
We undertook this systematic review with the aim of 
assessing the evidence regarding the use of stem cells in 
fracture healing and to establish what measures are being 
used to assess patient outcomes, in order to inform future 
research.
This review addressed four main questions:
1. What evidence is currently available assessing the ef-
fect of injection/implantation of stem cells on bone 
healing in fractures?
2. What interventions are being evaluated in terms of cell 
source, preparation and method of administration?
3. What methods do studies use to assess qualitative/
quantitative bone healing/callus formation?
4. What other outcome measures do studies use?
Methods
Prior to finalizing search criteria a protocol was written 
and prospectively registered on PROSPERO, with the 
registration ID CRD42019142041.
Study selection. Studies that matched the following crite-
ria were eligible for inclusion:
 Adults with any form of fracture, who did not have 
pre- existing bone defects.
  Utilization of stem cells to aid fracture healing, where 
stem cells could be from any source and provided by 
any mechanism. Fracture healing without the use of 
stem cells. Studies with no control group were also 
included.
 Studies where any other interventions were provided 
to both control and intervention arms were eligible.
Outcomes. Any outcomes were acceptable as an objec-
tive of this review was to map the outcomes used in stud-
ies. Key outcomes of interest were fracture healing, time 
to fracture healing, delayed or nonunion, the strength of 
bone post resolution, stem cell regeneration at the frac-
ture site, functional outcome (e.g. range of movement 
or patient- reported outcomes), quality of life, complica-
tions, and adverse events.
Study design. Randomized controlled trials (RCTs), non- 
randomized or observational studies, and case series in 
any publication format were included in the study. We 
also included research registrations and protocols for 
these designs to identify ongoing research.
Searches were developed and performed by an infor-
mation specialist (MH). A search strategy was developed 
in Ovid MEDLINE consisting of a set of terms for bone 
fractures combined with a set of terms for stem cells. Both 
text word searches in the title and abstracts of records 
and subject headings were included in the strategy. The 
wider review team were consulted during the drafting 
of the search strategy to ensure all relevant terms were 
included. No date or language limits were applied and 
the searches were designed to retrieve all study types. 
The strategy was tested in MEDLINE to ensure retrieval 
of key known studies and then adapted for use in all 
other resources searched. The following databases 
were searched from inception to 9 July 2019: MEDLINE 
(Ovid), EMBASE (Ovid), Cochrane Central Register of 
Controlled Trials (CENTRAL) (Wiley), Cochrane Database 
of Systematic Reviews (CDSR) (Wiley),  clinicaltrials. gov, 
and the World Health Organization (WHO) International 
Clinical Trials Registry Platform (WHO- ICTRP) to identify 
published, unpublished, and ongoing studies. The full 
search strategy for all sources is provided in the supple-
mentary material.
The results of the searches were de- duplicated using 
EndNote X8 (Clarivate Analytics, Philadelphia, Penn-
sylvania, USA) and uploaded to Covidence systematic 
review software (Veritas Health Innovation, Melbourne, 
Australia) for the screening process. Titles and abstracts 
were screened against the eligibility criteria by two inde-
pendent researchers, with any discrepancies between the 
decisions being resolved through discussion. Full- texts 
were obtained for those that were potentially eligible and 
these were screened against the eligibility by two inde-
pendent researchers, with any discrepancies resolved 
through discussion. Any additional references identified 
in reviews or included papers that had not been previ-
ously identified were also screened.
Two members of the team (AMo, AMi) developed and 
pilot tested a data extraction form using Google Forms 
(Mountain View, California, USA), designed around the 
study objectives. Once finalized, each eligible study was 
extracted by two independent researchers, with a third 
resolving any discrepancies.
Risk of bias assessment. Risk of bias assessments were 
completed based on study design, with case series be-
ing assessed against the Joanna Briggs Institute Critical 
Appraisal Checklist for case series,8 observational and non- 
randomised studies were assessed against the ROBINS- I 
assessment tool,9 and RCTs were assessed against the 
Cochrane Risk of Bias 2 tool.10 Each study was assessed by 
one researcher, with another researcher checking the first 
assessment. Where only a protocol or registration was 
available an assessment was not completed.
Synthesis of results. A narrative synthesis of studies to-
gether with tabulation of study characteristics and re-
sults was undertaken. Full details of the intervention 
BONE & JOINT OPEN 
A. MOTT, A. MITCHELL, C. MCDAID, M. HARDEN, R. GRUPPING, A. DEAN, A. BYRNE, ET AL624
Fig. 1
PRISMA flowchart of study records.
characteristics were described including stem cell type, 
preparation and mode of administration as well as out-
comes assessed and follow- up duration.
The key subgroups of interest were the source of stem 
cells, timing ,and method of administration.
Results
A total of 5,125 records were identified, and following 
de- duplication 3,695 records were identified for 
screening. A summary of the number of records at each 
stage of the review can be found in Figure 1.
There were 94 eligible studies,11-104 of these 26 were 
RCTs, 26 were observational/non- randomised studies, 
and 42 were case- series (19 prospective, 23 retrospec-
tive). A summary of study characteristics is provided in 
the supplementary material. The studies included acute 
fractures (23 studies), nonunion or pseudoarthrosis 
(66 studies), with five studies having a combination 
of these (Table  I). The earliest study was published in 
2005. Of the eligible studies, 29 (18 RCTs, nine observa-
tional/non- randomized, two case series) were identified 
as protocols or registrations and thus no results were 
available.
The quality assessment of the case series (online 
supplementary material) indicated that 66.7% (28/42) 
provided clear eligibility criteria, 54.7% (23/42) reliably 
applied the eligibility criteria, and 88.1% (37/42) clearly 
reported outcomes.
The quality assessments of the observational studies 
indicated all those with published data were at either 
moderate or serious risk of bias.
The quality assessments of the RCTs indicated that 
for all available trials there were either some concerns 
regarding potential bias or a high risk of bias. All quality 
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Table I. Site and type of fracture in included studies (n = 94).
Bone Number (%)
Any bone
  Acute 1 (1.1)
  Nonunion/pseudoarthrosis 1 (1.1)
  Combination 2 (2.1)
Any long bone
  Acute 1 (1.1)
  Nonunion/pseudoarthrosis 10 (10.6)
  Combination 0 (0)
Tibia
  Acute 8 (8.5)
  Nonunion/pseudoarthrosis 40 (42.5)
  Combination 1 (1.1)
Fibula
  Acute 2 (2.1)
  Nonunion/pseudoarthrosis 8 (8.5)
  Combination 0 (0)
Humerus
  Acute 3 (3.2)
  Nonunion/pseudoarthrosis 19 (20.2)
  Combination 0 (0)
Mandible
  Acute 3 (3.2)
  Nonunion/pseudoarthrosis 0 (0)
  Combination 0 (0)
Ulna
  Acute 1 (1.1)
  Nonunion/pseudoarthrosis 14 (14.9)
  Combination 0 (0)
Radius
  Acute 1 (1.1)
  Nonunion/pseudoarthrosis 10 (10.6)
  Combination 0 (0)
Metatarsal
  Acute 5 (5.3)
  Nonunion/pseudoarthrosis 1 (1.1)
  Combination 0 (0)
Any ankle bone
  Nonunion/pseudoarthrosis 2 (2.1)
Other (clavicle, scaphoid, pelvis)
  Acute 1 (1.1)
  Nonunion/pseudoarthrosis 2 (2.1)
assessment results are available in the supplementary 
material.
We also assessed the funding or support received 
for conduct of these studies, 65 studies did not report 
any details regarding support or funding, 23 reported 
funding for the study, and six reported partial support 
(provision of equipment, writing support, or other).
Eight of the 26 RCTs for which we identified published 
results; these eight had populations, methods, and 
outcomes that were too heterogeneous for meta- analyses 
to be appropriate (Table  II). We therefore completed a 
narrative synthesis.
Stem cell specific technique. The techniques related to 
the stem cells that are employed in the included studies 
varied in a number of aspects.
Bone marrow derived stem cells were used in 84 
studies (89.4%), seven used adipose derived cells (7.4%), 
and three used umbilical cord derived cells (3.2%). Two 
studies reported using more than one source of cells. 
Three studies (3.2%) did not report the source of the cells.
For those that used bone or adipose the majority used 
autologous cells with a small number using allografts. 
Details of donors of allografts was not specified in five 
studies, in one study donor eligibility was provided for 
all three types of tissue (bone, adipose, and umbilical) 
and one study used cadaveric donor tissue. Table  III 
summarises the sources of the cells used in the included 
studies.
Of the included studies that used bone marrow as 
a source of stem cells there were 64 (76.2%) that used 
the ilium, one (1.2%) used the tibia, one (1.2%) used a 
combination of these, and 18 (21.4%) did not report the 
source of the bone marrow used.
The methods used to aspirate cells were Reamer- 
irrigator- Aspirator (three, 3.2%), Jamshidi (seven; 7.4%), 
trocar (three; 3.2%), needle (24; 25.5%), other (two; 
2.1%), and was unreported in 55 (58.5%) studies. The 
method of aspiration was reported only in studies using 
bone as the source of cells.
Table  IV summarizes the methods of aspiration, 
concentration, and application of the cells used from the 
different sources.
Where reported, the type of centrifuge based system 
varied between the studies: Harvest System (eight; 
16.7%), Cobe (five; 10.4%), Magellan (three; 6.3%), 
Sepax (three; 6.3%), Aastrom (two; 4.2%), Sorvall (two; 
4.2%), Lymphodex (two; 4.2%), Angel (one; 2.1%), 
Regen (one; 2.1%), Cellution (one; 2.1%), Kubota (one; 
2.1%), and Percoll (one; 2.1%). Four studies noted the 
use of the Ficoll- Paque standard.
Concurrent interventions. Surgical fixation was the most 
common concurrent intervention provided with the stem 
cell intervention. Internal fixation was used in 28 studies, 
external fixation in 25 studies, 33 studies specified only 
the use of nailing, nine studies specified only screws, and 
one used a Kirschner wire.
Six studies reported using the diamond concept (this 
includes stem cells (osteogenic cells), osteoconductive 
scaffold, growth factors, and the mechanical environ-
ment), other studies did not use the diamond concept 
but did apply individual aspects of it alongside the stem 
cells.
Other interventions included: Mattie- Russe method, 
collagen scaffold, Hydroxyapatite scaffold, segmental 
excision, intermedullary rod, platelet lysate product, 
platelet rich fibrin, demineralized bone marrow, 
lypholised bone chips, osteotomy, beta- TCP, osseous 
BONE & JOINT OPEN 
A. MOTT, A. MITCHELL, C. MCDAID, M. HARDEN, R. GRUPPING, A. DEAN, A. BYRNE, ET AL626








fracture Site of fracture
Number of 
participants Healing definition
Zhang (2018)14 Bone 18 to 50 Nonunion Tibia 25 Specified only union
Zhai (2016)15 Bone > 18 Nonunion Humerus, ulna, 
femur, tibia, radius
63 Blurred fracture line, no pain on percussion, and 
functionality is suitable after removal of external 
fixation
Yuan (2010)16 Bone Not reported Nonunion Tibia/humerus 140 Callus Formation
Liebergall (2013)35 Bone 18 to 65 Acute Tibia 24 lack of pain during weight- bearing and bridging 
of three out of four cortices
Muthian (2018)38 Bone Not reported Combination Tibia 55 Specified only union
Mannelli(2017)42 Bone > 65 Acute Mandible 36 No healing outcome
Kim (2009)43 Bone Not reported Acute Any long bone 64 Study Specific Score base on callus formation
Castillo- Cardiel 
(2017)59
Adipose 17 to 59 Acute Mandible 20 Voxel counting of CT image
Table III. Cell Sources reported in included studies (n = 94).
Source Number (%)
Bone
  Autograft 74 (78.7)
  Allograft 3 (3.2)
  Unreported/unclear 5 (5.3)
  Both 2 (2.1)
Adipose
  Autograft 4 (4.2)
  Allograft 3 (3.2)
  Unreported/unclear 0 (0)
  Umbilical 3 (3.2)
  Unreported 3 (3.2)
Table IV. Aspiration, concentration, and application of the stem cells 












  Number of 
studies
50 3 2 52
  Mean (SD) 103.3 (119.6) 91.7 (72.2) 45.0 (7.1) 103.6 (117.9)
  Median (IQR) 60 (35.0 to 
105.0)
50 (50.0 to 
175.0)
45 (40 to 50) 60 (37.5 to 
115.0)
  Min to max 4 to 500 50 to 175 40 to 50 4 to 500
Method of 
concentration, n
  Centrifuge 46 2 1 48
  Culture 17 2 2 19
  SECCS 4 0 0 4




  Number of 
studies
36 0 1 36
  Mean (SD) 15.1 (13.5) NA 4.0 (N/A) 15.1 (13.5)
  Median (IQR) 10 (6.75 to 
20.0)
NA 4.0 (4.0 to 
4.0)
10 (6.75 to 
20.0)
  Min to max 1.5 to 50 N/A 4.0 to 4.0 1.5 to 50
Method of 
application, n
  Injection 34 1 2 37
  Implant 27 2 1 30
  On scaffold 9 2 0 11
  Unreported 9 0 0 10
Some studies reported more than one method and some studies did not 
report the method so the sum of the figures in the three method columns 
do not necessarily equal the overall.
*For each study a range or point estimate was taken, the mean of the 
ranges was taken to give a point estimate for each study, these were then 
used to calculate the mean, median, and standard deviation.
IQR, interquartile range; NA, not applicable; SD, standard deviation; 
SECCS, screen- enrich- combine circulating system.
matrix implantation, low- intensity pulsed ultrasound, 
and extracorporeal shock wave therapy.
In all, 26 studies provided details of further treatment 
required or the guidelines that were used to guide further 
treatment.
Outcomes used. Overall, 89 of the included studies re-
ported use of a healing outcome. Time- to- healing was re-
ported in 28 of these, proportion healed at a given time 
point was reported in 40, 14 reported both of these, four 
provided an average measured healing score for at least 
one time point, and three did not make clear the how the 
measure was defined despite specifying the outcome.
Healing outcomes fell into three broad categorisa-
tions: only radiological outcomes (51 studies), only clin-
ical outcomes (two studies), and combined radiological 
and clinical outcomes (31 studies); five studies did not 
provide a clear enough healing definition to be catego-
rized. Table V summarises the frequency of the compo-
nents used to assess healing.
Outcomes other than healing were grouped into 
seven categories: quality of life, pain, injury/population 
specific, range of movement, adverse events, and cellular 
categorization. Table  VI records the number of studies 
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Table V. Summary of the frequency of healing outcome components (n = 
89).
Measure
Number of studies (% 
of studies reporting 
healing)
No specific radiological measure or definition 
given*
27 (30.3)
Qualitative radiological evaluation 
without scoring
  Blurred fracture or no fracture line 9 (10.1)
  Callus formation 28 (31.5)
  Cortices bridging (75%) 22 (24.7)
Qualitative radiological evaluation 
with scoring
  Radiological Union Scale in Tibial fractures 
(RUST)105
2 (2.2)
  Lane and Sandhu criteria106 2 (2.2)
  Tiedemann criteria107 1 (1.1)
  Study specific criteria 2 (2.2)




  Voxel or pixel counting 1 (1.1)
  Callus volume measure 2 (2.2)
  Hounsfield units 4 (4.5)
  New bone ratio 1 (1.1)
  Bone mineral content 2 (2.2)
Qualitative clinical evaluation
  No pain on compression, palpatation, or 
percussion
3 (3.4)
  Weightbearing/partial weightbearing 13 (14.6)
  Removal of external fixation 4 (4.5)
  Qualitative clinical evaluation with scoring
  Specific threshold on pain scale 3 (3.3)
*Includes studies that defined healing as “bony fusion”, “union”, 
“consolidation”, or “bone formation” as these are all non- specific.
Table VI. Patient- reported outcomes and range of movement.
Outcome
Number of studies 
(%)
Quality of life
  EQ- 5D 6 (6.4)
  SF-36 or SF-12 or SF- HLQ 8 (8.5)
  Satisfaction (any rating scale) 2 (2.1)
  Visual analogue scale 1 (1.1)
  No specified measure 1 (1.1)
Pain
  Visual analogue scale 15 (16.0)
  PROMIS (interference) 1 (1.1)
  Numeric rating scale 1 (1.1)
  Other 2 (2.1)
Injury or population- specific measures* n = 14
  DASH 5 (5.3)
  OSS 1 (1.1)
  LEFS 3 (3.2)
  FAOS 2 (2.1)
  FAAM 2 (2.1)
  SMFA 1 (2.1)
  KOOS 1 (1.1)
  Time to return to sport 2 (2.1)
  Time to return to daily activities 1 (1.1)
  Range of movement* 6 (6.4)
*These outcomes would not be an appropriate measure for all studies.
DASH, Disabilities of the Arm Shoulder and Hand; EQ- 5D, EuroQol- 5 
Dimension; FAAM, Foot and Ankle Ability Measure; FAOS, Foot and Ankle 
Outcome Score; KOOS, Knee Injury and Osteoarthritis Outcome; LEFS, 
Lower Extremity Function Score; OSS, Oxford Shoulder Score; PROMIS, 
Patient- Reported Outcomes Measurement Information System; SF-12, 12- 
item Short Form Survey; SF-36, 36- item Short Form Survey; SF- HLQ, Short 
Form- Health and Labour Questionnaire; SMFA, Short Musculoskeletal 
Functional Assessment.
using patient reported outcomes and range of move-
ment measures.
Adverse events. The method used for adverse event re-
porting was reported in 46 (48.9%) studies. However, 
only 7 (7.4%) studies provided clear definitions for how 
events would be classified.
Reactions to stem cells were assessed in five studies, 
complications at the harvest site were assessed in 24 
studies, infection at the administration site was assessed 
in 35 studies and complications with metalwork were 
assessed in 12 studies. Of the five studies assessing reac-
tion to stem cells one study reported any immediate reac-
tion, with one study reporting an allergic skin reaction in 
one patient.14 This occurred after the participant received 
an injection of 20 ml of autologous bone marrow concen-
trated by centrifuge for their tibial nonunion, no details 
are provided regarding the timing of this event. It is noted 
that it was managed with oral antihistamine.
Other adverse events that were reported to be assessed 
by other studies, although did not necessarily occur, 
were: refracture (one study), haematoma (four studies), 
oedema (two), fistula development (one), pulmonary 
embolism (two), anaphylaxis (one), neoplasm/malig-
nancy (four), wound dehiscence (two), nerve injury 
(two), nerve palsy (one), malunion (two), chronic pain 
at administration site (one), amputation (one), charcot 
arthropathy (one), skin necrosis (one), compartment 
syndrome (one), deep vein thrombosis (one), avascular 
necrosis (one), arthrofibrosis (one), heart failure (one), 
and excessive bone formation (one).
Cellular categorization. Attempts to categorize or identi-
fy the cells that were isolated and used was made in 33 
(35.1%) of the included studies.
Discussion
Summary of evidence. We identified 94 studies that 
reported the use of stem cells for fracture healing in 
adults by searching literature databases and research 
registries; of these, 29 had yet to publish any results. 
Only eight RCTs were available with results. For the 
randomized evaluations that had available results, the 
eligibility criteria, methods relating to the interven-
tion, and outcomes were too heterogeneous to enable 
meta- analyses.
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Of the studies with reported results the quality assess-
ment suggested that all RCTs and observational studies 
had some concerns regarding bias or were at high risk 
of bias. Therefore, there is not yet sufficient high- quality 
evidence for us to draw any conclusions regarding the effi-
cacy of stem cells for fracture healing. The studies that were 
included were able to provide details regarding the study 
populations, methods, and outcomes that will be valuable 
in the design of future studies that can be used to assess 
efficacy.
Many of the issues identified here correspond with those 
raised by the International Society for Cellular Therapy (ISCT) 
regarding the use of stem cell therapies and other system-
atic reviews on the topic.108-110 The ISCT identified that many 
cellular therapies do not have sufficient evidence from basic 
lab work to clinical evaluation and often they lack a standard-
ized approach to confirm the quality and consistency of the 
cells used. Our review both confirms these issues and adds 
to this evidence that for studies assessing stem cells in frac-
ture healing there is also a lack of comparable outcomes for 
assessment of fracture healing.
Stem cell technique. The majority of studies utilized au-
tologous bone marrow sourced from the ilium, centrif-
ugation of the aspirated marrow for concentration of 
cells, and injected or implanted the concentrated cells 
with no scaffold. However, even among these studies 
there was heterogeneity in the methods of cellular aspi-
ration, concentration methodology (varying centrifuge 
technology), and concurrent interventions.
The heterogeneity of these methods is unlikely to 
change in future research, as the availability of different 
commercial kits will only increase. Therefore, in order 
to provide a more standardized and comparable inter-
vention there is a need for better and more consistent 
categorization of the type and amount of concentrated 
cells used in any study and for this to be reported.
Some studies have also suggested that the availability 
and the regenerative potential of cells change with age 
and that this may differ with the source of the cells.111,112 
Future studies should consider the age, source, and the 
available quantity and quality of the cells, this would 
allow clinicians to make decisions on the appropriate 
approach for patients of different ages.
Reporting of key aspects of the intervention in the 
included studies was poor. Given that the source, 
preparation, and application of these cells are likely to 
impact upon the efficacy of the intervention this infor-
mation should be a minimum reporting requirement 
for any future studies. As well as this a larger focus 
should be given to the type, quantity and quality of the 
cells used in these studies. One way this could be done 
is to use the guidelines produced by the ISCT, these 
outline the criteria for defining a mesenchymal stem 
cell and the appropriate classification and reporting of 
these interventions.113,114
Healing outcomes. Increased rates of healing are ben-
eficial as it reduces the need for further intervention, 
complications, and nonunions. One of the purported 
benefits of using stem cells is that it will accelerate the 
healing process. Therefore, time- to- healing may be an 
important measure of healing. Time- to- healing data is 
presented in 28 of the included studies however few 
reported follow- up schedules that would allow reason-
able analyses to be undertaken to assess differences be-
tween groups. While it is possible to use an appropriate 
analysis for interval- censored data, such as this, there 
are issues that arise when the outcome has both radi-
ological and clinical aspects and as the length of time 
between follow- ups increases.115 Any future studies 
considering a time- to- healing outcome should carefully 
consider the study follow- up schedule required to as-
sess any differences in time- to- healing between groups 
in the relevant bone.
Nearly one- third (n = 27; 30.3%) of the included 
studies did not provide a specific definition of healing 
and the healing definitions that were most utilized were 
subjective. The use of quantitative assessment was low. 
Healing outcomes should be more well defined and 
further research is required to define and validate these 
outcomes.
The most appropriate methods for assessing frac-
ture healing may differ with the site and type of frac-
ture. However, even bone specific reviews and fracture 
healing reviews have found that there is heterogeneity of 
outcomes with similar characteristics to those included 
in our review.116,117 A well developed core outcome set 
(COS) that covers the appropriate outcomes, in terms 
of assessment and measure that can be used across 
fractures or for specific populations would reduce 
this heterogeneity for future research.118 One previous 
attempt at developing a COS for fracture healing in 
osteoporosis notes the need for measuring time to 
union but recognizes identical issues that are raised 
in this review regarding the heterogeneity of potential 
outcomes.119 The need for identifying the appropriate 
outcomes was the top research requirement in a recent 
James Lind Alliance Priority Setting Partnership project 
regarding fractures in older people.120 The development 
of a COS must be done in alignment with pre- existing 
international standards and taking into consideration 
patient and public opinion.121
Other outcomes. The other measures used in the in-
cluded studies covered the main domains that might 
be expected in fracture trials (pain, quality of life, out-
comes specific to the injury, and range of movement). 
However, the vast majority of studies did not report 
these outcomes, especially when compared to the 
large number that reported a healing outcome. Had 
more included studies provided a measure of pain or 
quality of life these could have provided an indication 
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of effectiveness of stem cells on these outcomes.122 
The development and uptake of a COS with the in-
volvement of patients and the public would resolve 
this.
Strengths and limitations. Our review provides a compre-
hensive overview of the methods being used to evaluate the 
use of stem cells for fracture healing. We included studies 
that are yet to be published or that were never completed. 
While these studies could not provide data on the efficacy 
of the intervention this allowed us to assess the full range of 
methods that are being utilized in these studies.
It should be noted that a large number of studies were 
identified (but excluded) that utilized a bone graft or bone 
marrow aspiration and injection without concentration. 
These grafts may have contained stem cells but the authors 
made no reference to the preparation, isolation, or inclu-
sion of stem cells. This intervention was used as a control 
intervention to compare to concentrated stem cells in some 
studies, therefore studies using this intervention alone were 
not included as they cannot provide details related to the 
specific intervention objectives of this review. These studies 
may have been able to provide some information about the 
extraction of bone marrow and the outcomes used for frac-
ture healing.
A large number of studies were also excluded for not 
being available in English. This may limit the comprehen-
siveness of this review. This may be especially important as 
international regulatory requirements for stem cell research 
differ quite widely, especially with regards to the sourcing 
and preparation of such cells.123,124
There is a clear need for standardization across studies 
and work is required to enable this before future research 
is conducted. Such work may include the development of 
a COS, minimum reporting standards, and co- ordination 
of research into different populations. This should be done 
in alignment with international standards and patient and 
public opinion.
Take home message
  - There are few high- quality published studies assessing the 
use of stem cells for fractures.
  - Future studies need to ensure that there is appropriate 
standardisation of procedures and categorisation of cells, as well as 
meeting international standards for the conduct and reporting of these 
studies.
Twitter
Follow C. McDaid @YorkTrialsUnit
Follow M. Harden @crd_york
Follow A. Byrne @AilishByrne2
Supplementary material
  Tables showing search strategies, study character-
istics, Joanna Briggs Institute case series assess-
ments, ROBIS assessments of non- randomized 
and observational studies, and ROB2 assessments of 
randomized controlled trials.
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